Curileum Discovery

Company profile

Curileum Discovery company profile

Curileum Discovery is a biotechnology company in London discovering and developing novel therapeutics to intervene early in the development of severe GI diseases. ULI-015 is a novel small molecule that the company's scientists discovered that redirects precancerous cell production in polyps to healthy tissues. Daily oral treatment profoundly reduced polyps after three months in a porcine bowel cancer model (255 necrotic polyps, 1 progressive polyp). After six months, polyps regressed and fused with healthy tissue (571 regressed polyps, 1 progressive polyp). The company has developed a large scale, one-step method to isolate gram levels of ULI-015 from a plant source. The company anticipates obtaining Orphan Drug Designation to test ULI-015 in familial adenomatous polyposis (FAP) patients. Curileum is based at St Mark’s Hospital in London, Europe’s oldest and largest registry of FAP patients. ULI-015 will target the large sporadic bowel cancer market by treating high-risk individuals identified in bowel screening programmes. Curileum is fundraising to advance ULI-015 to clinical PoC.